 CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has extended its partnership with Takeda Pharmaceutical Company Limited TSE: 4502NYSE: TAK to diagnose patients with certain genetic disorders. 